QBIO News and Press, Q BioMed Inc

Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...

Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...

thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Q BioMed Inc (QBIO) is expected to report for quarter end 2023-05-31

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe PR Newswire Company's Liver Cancer Drug Candidate IP Portfolio strengthened Company provides operational update on strategic opportunit...

Q BioMed ( OTCQB:QBIO ) said its chemotherapeutic Uttroside B is expected to receive a patent in the U.S linked to liver cancer The company noted that it received a notice of allowance from the U.S. Patent Office for the patent titled 'Uttroside-B and Derivatives Thereof as Therapeut...

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office PR Newswire Uttroside B Has Shown Promising Results in Initial Pre-Clinical Testing NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Q Bio...

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. PR Newswire Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK ...